Document is current
Any future updates will be listed below
-
Authors
Abbass, Nadia J.
Shaia, Jacqueline K.
Shukla, Priya
Cohen, Devon
Kaelber, David C.
Talcott, Katherine E.
Singh, Rishi P. https://orcid.org/0000-0001-5859-8162
-
Funding
Funding for this research was provided by:
Case Western Reserve University School of Medicine | Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (UL1TR002548, UL1TR002548, UL1TR002548, UL1TR002548, UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A))
U.S. Department of Health & Human Services | NIH | National Eye Institute (T32 EY024236)
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 31 January 2025
Accepted: 4 February 2025
First Online: 26 February 2025
Competing interests
: RPS reports personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Jannsen. KET: Alimera (consultant), Apellis (consultant), Bausch and Lomb (consultant), Eyepoint (consultant), Genentech (consultant, speaker's bureau), Iveric Bio (speaker's bureau), Regeneron (research), Regenxbio (research), Zeiss (research). No conflicting relationship exists for any other author.
